Ann: Azer-cel demonstrates two additional Complete Responses, page-259

Itis wonderful to see the fresh debate and renewed enthusiasm on these threads.

It was beginning feel like the whole site had fallen into the famous Dickens novel....

A Tale of TwoCities (or in this case, Bio-techs)

As Dickens writes ... “It was the best of times, it was the worst of times, it was the age of wisdom, it was the age of foolishness, …” of course, he was contrasting Paris and London during the turmoil of the French Revolution.

Overthe last year or so these threads have felt like Paris (IMU), with posters living in upheaval and uncertainty, and all the while visitors from London (RAC) relentlessly popping in to jeer, while pretending to warn the locals of their impeding doom.I have found it very strange. It suspect that the mayor of ‘London’, Dr Tillett,may have felt the same over there.

It should be clear to most that while both IMU and RAC are working in the cancer space, that is where the similarity ends. Different cancers, different methods,different treatments, different time frames, different ... never mind. I suspect that RAC holders have some concerns that any IMU success may impact what RAC are trying to achieve. As I said before, I have found this very strange because there is certainly room for more than one successful Ozzie biotech .

Imugene (IMU) has just announced some very impressive results. Yes, the cohort is small, but growing, and safety doesn’t appear to be an issue. The enrolment has been slower than first announced but this is science at the cutting edge and at least Team IMU is responsive to what they see in front of them (think ...IL-2). As others have clearly stated, acer-cel has brought a majority of these DLBCL patients back from almost certain death. Remember, this is one of the most aggressive forms of non-Hodgkin’s lymphoma. If you look at the results objectively and honestly, they are certainly impressive up to this point.

Ihave always believed that the long-term purpose of the acer-celacquision was all about how it might play with our onCARlytic program.Of course, it must gain registration in its own right first, and this would bring much needed income to the IMU coffers sooner than later.

AsI said above, there is some wonderful discussion now flowing.

•Oh @davybabyk, welcome back. To me, IMU’s most reliable and best researched poster ... always ready to include solid ‘links’ for those who wish to followthrough. As results continue to flow (I hope), I look forward to see your views and research back on these threads.

•Hey @DickyB , several nice points there, so I won’t lift your whole quote. To the point and well said mate. To @Fact Finder , a similarly excellent and ‘to the point post’. Well said.

•I haven’t noticed @kingfedex here before but he/she has nailed it, in my opinion,when they say “It's important to note DLBCL has many subtypes, and the prognosis can be very different. Something has to be working to get these results.” Some here believe that cracking DLBCL is straightforward ...nothing could be further from the truth.

•Until I see science to the contrary, I will have to agree with Bavarian, “No use throwing IL2 in with CF33, it will do nothing, at least I think so - could be good for oncarltyics though”. Let’s see.

Thanksalso to T&P, and many others, for your upbeat outlook on these thread.

**As an aside, I would suggest that people don’t ignore the neoPOLEM trial which is about to start (yes, another that is a little delayed). This may wellbe a little firecracker and when I get a little more time I will come back to discuss it a little more.

I’ll finish with another saying from the masterful Charles Dickens. It reminds me of the virtuoso Yuman Fong ...

“The most important thing in life is to stop saying ‘I wish’ and start saying ‘I will.’ Consider nothing impossible,then treat possibilities as probabilities.”

I think that’s how Yuman Fong works ... treating possibilities as probabilities.

As always, just the opinion of one poster